Sigyn Therapeutics, Inc. has released details about CardioDialysis, a medical device designed to reduce major adverse cardiovascular events through continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. Cardiovascular disease remains the leading cause of death worldwide, with current therapies like LDL-C reducing statins lowering MACE incidence by approximately 25%. However, lipoprotein apheresis technologies have demonstrated the potential to reduce these events by 75-95%, according to the American Heart Association.
The widespread adoption of existing apheresis technologies has been limited by complex, multi-component designs that lack global delivery infrastructure. For example, the FDA-approved Kaneka LIPOSORBER procedure requires a plasma separation column, two LIPOSORBER cartridges, custom blood tubing sets, a blood warmer, multiple bags of replacement fluids, multiple bags of regeneration fluids, four waste bags, and multiple pumps. This complexity restricts access to fewer than 60 specialized apheresis centers in the United States, despite approximately 600,000 treatments having been administered to more than 6,000 patients worldwide.
CardioDialysis represents a significant advancement by fully integrating plasma separation and therapeutic adsorption within a single device that can be deployed on existing dialysis machines. The technology is designed to be deployable on dialysis machines already located in more than 5,000 hospitals and 7,500 dialysis clinics in the United States alone. Compared to the LIPOSORBER system, CardioDialysis addresses a broader range of cardiovascular disease targets, processes the bloodstream with greater efficiency, and eliminates the need for replacement fluids, additional pumps, or other auxiliary components.
Within the emerging field of subtractive medicine, CardioDialysis is the first therapy to integrate plasma separation and therapeutic adsorption within a single device. The technology aims to reduce circulating inflammatory mediators that fuel cardiovascular disease progression while simultaneously lowering levels of cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other major adverse cardiovascular events. This dual approach overcomes the inherent limitations of single-target drugs currently available.
The potential impact of this technology is substantial, considering that 15-20% of major adverse cardiovascular events result in death. The successful clinical advancement of CardioDialysis could save thousands of lives each year by providing broader access to effective cardiovascular intervention. The technology's compatibility with existing dialysis infrastructure represents a practical solution to the deployment challenges that have limited previous apheresis technologies.
Sigyn Therapeutics is developing additional applications for its blood purification technology, including ImmunePrep to optimize immunotherapeutic antibody delivery for cancer treatment, ChemoPrep to enhance targeted chemotherapy delivery, and ChemoPure to reduce chemotherapy toxicity. More information about the company's developments can be found at https://www.SigynTherapeutics.com. The original announcement was published on https://www.newmediawire.com.
